Loading organizations...
§ Private Profile · 700 Park Offices Dr Ste 200, Durham, North Carolina, 27709, United States
Developing oncology therapies to protect bone marrow from chemotherapy toxicity. First commercial product: COSELA (trilaciclib).
G1 Therapeutics is a clinical and commercial-stage biopharmaceutical company based in Research Triangle Park, North Carolina, that develops oncology therapies to protect bone marrow from chemotherapy toxicity. The enterprise focuses on commercializing its primary product, COSELA, while advancing next-generation cancer drugs targeting specific protein kinases involved in cell division. Prior to operating as a subsidiary of Pharmacosmos Therapeutics, the business secured a $47 million Series C funding round and subsequently raised $108.6 million during its 2017 initial public offering on the NASDAQ under the ticker symbol GTHX. The firm received financial backing from notable early investors including Hatteras Venture Partners, and its executive leadership team has featured industry veterans such as Jack Bailey and Raj Malik. Norman Sharpless and Jay Strum originally founded the organization in 2008 to translate university research discoveries into treatments for patients.
G1 Therapeutics has raised $93.0M across 3 funding rounds.
G1 Therapeutics has raised $93.0M in total across 3 funding rounds.
G1 Therapeutics has raised $93.0M across 3 funding rounds. Most recently, it raised $47.0M Series C in May 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2016 | $47M Series C | Bihua Chen | Catalio Capital, Hatteras Venture Partners, Ryan Allis, AJU IB Investment, Cowen Private Investments, Eshelman Ventures, Franklin Templeton, Lumira Ventures, Medimmune Ventures, Mountain Group Partners, RA Capital Management, Rock Springs Capital, Tavistock Group | Announced |
| Feb 1, 2015 | $33M Series B | Fred Eshelman, Peter Kolchinsky | Catalio Capital, Hatteras Venture Partners, Ryan Allis, Boxer Capital, Lumira Ventures, Medimmune Ventures, Mountain Group Partners | Announced |
| Oct 1, 2013 | $13M Series A | Michael Gutch | Catalio Capital, Hatteras Venture Partners, Ryan Allis, Mountain Group Partners | Announced |
G1 Therapeutics is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of next-generation small molecule therapies aimed at improving outcomes for cancer patients. Its flagship product, COSELA™ (Trilaciclib), is designed to reduce chemotherapy-induced myelosuppression in patients undergoing treatment for extensive-stage small cell lung cancer. The company serves oncology patients and healthcare providers by addressing critical side effects of chemotherapy and advancing targeted cancer treatments, including therapies for breast, colorectal, lung, and bladder cancers. G1 Therapeutics has demonstrated growth momentum through its expanding clinical pipeline and strategic licensing agreements, including partnerships for global development and commercialization of its drug candidates[1][2][3][4].
Founded in 2008 and headquartered in Research Triangle Park, North Carolina, G1 Therapeutics was established with a focus on oncology innovation. The company’s leadership includes CEO John E. Bailey Jr. and Chief Medical Officer Dr. Rajesh K. Malik, among others. The idea for G1 Therapeutics emerged from the need to develop therapies that not only target cancer cells but also protect patients from the toxic effects of chemotherapy, a pivotal focus that has guided its clinical development and commercial strategy. Early traction was marked by the successful launch of COSELA and advancing multiple candidates through clinical trials, positioning G1 as a notable player in oncology therapeutics[1][2][3].
G1 Therapeutics operates at the intersection of biotechnology and oncology, riding the trend toward precision medicine and supportive cancer care. The timing is critical as cancer treatment increasingly integrates targeted therapies that minimize collateral damage to healthy cells. Market forces such as rising cancer incidence, demand for better supportive care, and advances in molecular biology favor G1’s approach. By developing therapies that optimize chemotherapy, G1 influences the broader ecosystem by enabling more effective and tolerable cancer treatment regimens, potentially setting new standards in oncology care[1][2][4].
Looking ahead, G1 Therapeutics is poised to expand its impact through continued clinical advancements and commercialization of its pipeline products. Trends such as personalized medicine, combination therapies, and improved cancer survivorship will shape its journey. As it leverages its clinical expertise and partnerships, G1’s influence may grow beyond supportive care into broader oncology treatment paradigms, reinforcing its role as a leader in next-generation cancer therapies[1][2][4].
G1 Therapeutics has raised $93.0M in total across 3 funding rounds.
G1 Therapeutics's investors include Bihua Chen, Catalio Capital, Hatteras Venture Partners, Ryan Allis, AJU IB Investment, Cowen Private Investments, Eshelman Ventures, Franklin Templeton, Lumira Ventures, MedImmune Ventures, Mountain Group Partners, RA Capital Management.